The antibody-mediated targeted delivery of interleukin-10 inhibits endometriosis in a syngeneic mouse model

Kathrin Schwager, Schwager K, Frank Bootz, Bootz F, Patrick Imesch, Imesch P, Kaspar M, Manuela Kaspar, Eveline Trachsel, Trachsel E, Dario Neri
Human Reproduction · 2011 · vol. 26(9) , pp. 2344–2352 · doi:10.1093/humrep/der195 · PMID:21705369 · W2166047102
Lab / animal OA: bronze CC0 ⤵ 19 in-corpus citations
📄 Open PDF View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-11 ⓘ

The F8 antibody specifically targets endometriotic lesions in a mouse model, enabling in vivo imaging and therapeutic delivery of anti-inflammatory IL-10 to reduce lesion size.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

BACKGROUND: Endometriosis is still a highly underdiagnosed disease, and the current medical and surgical treatment of endometriosis is associated with a high recurrence rate. This study investigates the use of derivatives of the human antibody F8, specific to the alternatively spliced extra-domain A of fibronectin (Fn), for the imaging and treatment of endometriosis. METHODS: Immunohistochemistry and immunofluorescence was used to evaluate antigen expression in endometriotic tissue of human endometriosis and of a syngeneic mouse model of the disease. The in vivo targeting performance of a fluorescent derivative of the F8 antibody was assessed by imaging mice with endometriosis using a near-infrared fluorescence imager, 24 h following i.v. injection of the antibody conjugate. Furthermore, the mouse model was used for therapy experiments using two recombinant F8-based immunocytokines [F8-interleukin-10 (IL10) and F8-IL2] or saline for the treatment groups. RESULTS: A very strong vascular expression of splice isoforms of Fn and of tenascin-C was observed in human endometriotic lesions by immunohistochemistry and immunofluorescence techniques. After i.v. administration, a selective accumulation of the F8 antibody in endometriotic lesions could be observed in a syngeneic mouse model. These targeting data were used as a basis for therapy experiments with a pro-inflammatory (F8-IL2) and an anti-inflammatory (F8-IL10) cytokine fusion protein of the F8 antibody. The average lesion size in the F8-IL10 treatment group was clearly reduced compared with the saline control group and with the F8-IL2 group, for which no therapeutic effects were observed. CONCLUSIONS: The F8 antibody targets endometriotic lesions in vivo in a mouse model of endometriosis and may be used for the non-invasive imaging of the disease and for the pharmacodelivery of anti-inflammatory cytokines, such as IL10.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Antibodies, Monoclonal Endometriosis Interleukin-10 Alternative Splicing Alternative Splicing Animals Animals Antibodies, Monoclonal Antibodies, Monoclonal Antibodies, Monoclonal, Humanized Antibodies, Monoclonal, Humanized Cytokines Cytokines Cytokines Endometriosis Endometriosis Endometriosis Female Female Fibronectins

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (64)

Cited by (21)

Source provenance

europepmc
last seen: 2026-10-14T06:08:39.101224+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:09:10.644269+00:00
License: CC0 · commercial use OK